Skip to main content
SpringerLink
Log in

Management of Male BRCA Mutation Carriers

  • Chapter
  • First Online:
Managing BRCA Mutation Carriers

Abstract

Male breast cancer (MBC) accounts for <1% of all breast cancer diagnosed annually in the USA. Approximately 20% of affected men have a positive family history of breast cancer and 5–10% are associated with germline cancer susceptibility gene mutations. Unfortunately, with such small numbers, the research opportunities and data available on the biology, diagnosis, and management of male breast cancer have been limited. The management of male breast cancer, therefore, has been extrapolated from the available evidence derived in studies of female breast cancer, in particular, postmenopausal, estrogen receptor-positive (ER+) tumors. This strategy appears to be associated with similar overall outcomes when MBC patients are matched to female breast cancer (FBC) patients. However, increasing evidence has suggested that there are significant differences in the biology of MBC compared to the disease in females. These differences may eventually translate into alternative management options for MBC patients. Genetic susceptibility genes, in particular BRCA2, play a role in a subset of MBCs and offer an attractive springboard for a variety of biological studies that hold the promise of providing insight into this rare disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Deb S, Lakhani SR, Ottini L, et al. The cancer genetics and pathology of male breast cancer. Histopathology. 2016;68(1):110–8.

    Article  PubMed  Google Scholar 

  2. Cancer Facts and Figures 2016. American Cancer Society.

    Google Scholar 

  3. Jemal A, Siegel R, Xu J, et al. Cancer statistic. CA Cancer J Clin. 2010;60:277–300.

    Article  PubMed  Google Scholar 

  4. Giordano SH, Cohen DS, Buzdar AU, et al. Breast carcinoma in men: a population-based study. Cancer. 2004;101:51–7.

    Article  PubMed  Google Scholar 

  5. Korde LA, Zujewski JA, Kamin L, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114–22.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ferzoco RM, Ruddy KJ. The epidemiology of male breast cancer. Curr Oncol Rep. 2016;18:1–6.

    Article  CAS  PubMed  Google Scholar 

  7. Haraldsson K, Loman N, Zhang QX, et al. BRCA germ-line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998;58:1367–71.

    CAS  PubMed  Google Scholar 

  8. Anderson WF, Althius MD, Brinton LA, et al. Is male breast cancer similar or different than female breast cancer? Breast Cancer Res Treat. 2004;83:77–86.

    Article  PubMed  Google Scholar 

  9. Ewertz M, Holmberg L, Karjalainen S, et al. Incidence of male breast cancer in Scandinavia, 1943–1982. Int J Cancer. 1989;43:27–31.

    Article  CAS  PubMed  Google Scholar 

  10. Newman J. Breast cancer in men and mammography of the male breast. Radiol Technol. 1997;69:17–28.

    CAS  PubMed  Google Scholar 

  11. Heller KS, Rosen PP, Schottenfeld D, et al. Male breast cancer: a clinicopathologic study of 97 cases. Ann Surg. 1978;188:60–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Braunstein GD. Gynecomastia. N Eng J Med. 1993;328:490–5.

    Article  CAS  Google Scholar 

  13. Thomas DB, Jimenez LM, McTiernan A, et al. Breast cancer in men: risk factors with hormonal implications. Am J Epidemiol. 1992;135:734–48.

    Article  CAS  PubMed  Google Scholar 

  14. Mabuchi K, Bross DS, Kessler II. Risk factors for male breast cancer. J Natl Cancer Inst. 1985;74:371–5.

    CAS  PubMed  Google Scholar 

  15. Casagrande JT, Hanisch R, Pike MC, et al. A case-control study of male breast cancer. Cancer Res. 1988;48:1326–30.

    CAS  PubMed  Google Scholar 

  16. Ewertz M, Holmberg L, Tretli S, et al. Risk factors for male breast cancer—a case control study from Scandinavia. Acta Oncol. 2001;40:467–71.

    Article  CAS  PubMed  Google Scholar 

  17. Hsing AW, McLaughlin JK, Cocco, et al. Risk factors for male breast cancer (United States). Cancer Causes Control. 1998;9:269–75.

    Google Scholar 

  18. Kanhai RC, Hage JJ, van Diest PJ, et al. Short term and long term histologic effects of castration and estrogen treatment on breast tissue of 14 male to female transsexuals in comparison with two chemically castrated men. Am J Surg Pathol. 2000;24:74–80.

    Article  CAS  PubMed  Google Scholar 

  19. Thellenberg C, Malmer B, Tavelin B, et al. Second primary cancers in men with prostate cancer: an increased risk of male breast cancer. J Urol. 2003;169:1345–8.

    Article  PubMed  Google Scholar 

  20. Thomas DB, Rosenblatt K, Jimenez LM, et al. Ionizing radiation and breast cancer in men (United States). Cancer Causes Control. 1994;5:9–14.

    Article  CAS  PubMed  Google Scholar 

  21. Hill A, Yagmur Y, Tran KN, et al. Localized male breast carcinoma and family history. An analysis of 142 patients. Cancer. 1999;86:821–5.

    Article  CAS  PubMed  Google Scholar 

  22. Johnson KC, Pan S, Mao Y. Risk factors for male breast cancer in Canada, 1994–1998. Eur J Cancer Prev. 2002;11:253–63.

    Article  CAS  PubMed  Google Scholar 

  23. Rosenblatt KA, Thomas DB, McTiernan, et al. Breast cancer in men: aspects of familial aggregation. J Natl Cancer Inst. 1991;83:849–54.

    Google Scholar 

  24. Haraldsson K, Loman N, Zhang QX, et al. BRCA2 germ line mutations are frequent in male breast cancer patients without a family history of the disease. Cancer Res. 1998;58:1367–71.

    CAS  PubMed  Google Scholar 

  25. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA 2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480–90.

    Article  CAS  PubMed  Google Scholar 

  27. Tai YC, Domchek S, Parmigiani G, et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst. 2007;99:1811–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Silvestri V, Zelli V, Valentini V, et al. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer. 2017;123(2):210–8.

    Article  CAS  PubMed  Google Scholar 

  29. King TA, Li W, Brogi E, et al. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis. Ann Surg Oncol. 2007;14(9):2510–8.

    Article  PubMed  Google Scholar 

  30. Kinzler KW, Vogelstein B. Cancer-susceptibility genes. Gatekeepers and caretakers. Nature. 1997;386(6627):761, 763.

    Google Scholar 

  31. Ottini L, Silvestri V, Rizzolo P, et al. Clinical and pathologic characteristics of BRCA—positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy. Breast Cancer Res Treat. 2012;134:411–8.

    Article  CAS  PubMed  Google Scholar 

  32. Venkitarraman AR. Cancer Susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002;108(2):171–82.

    Article  Google Scholar 

  33. Silvestri V, Barrowdale D, Mulligan AM, et al. Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Res. 2016;18(1):15.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Piscuoglio S, Ng CK, Murray MP, et al. The genomic landscape of male breast cancers. Clin Cancer Res. 2016;22(16):4045–56.

    Article  CAS  PubMed  Google Scholar 

  35. Stalsberg H, Thomas DB, Rosenblatt KA, et al. Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men. Cancer Causes Control. 1993;4:143–51.

    Article  CAS  PubMed  Google Scholar 

  36. Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg. 2001;182:389–92.

    Article  CAS  PubMed  Google Scholar 

  37. Muir D, Kanthan R, Kanthan SC. Male versus female breast cancers. A population- based comparative immunohistochemical analysis. Arch Pathol Lab Med. 2003;127:36–41.

    CAS  PubMed  Google Scholar 

  38. Curigliano G, Colleoni M, Renne G, et al. Recognizing features that are dissimilar in male and female breast cancer: Expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. Ann Oncol. 2002;13:895–902.

    Article  CAS  PubMed  Google Scholar 

  39. Evans GF, Anthony T, Turnage RH, et al. The diagnostic accuracy of mammography in the evaluation of male breast disease. Am J Surg. 2001;181:96–100.

    Article  CAS  PubMed  Google Scholar 

  40. Yang WT, Whitman GJ, Yuen EH, et al. Sonographic features of primary breast cancer in men. AJR Am J Roentgenol. 2001;176:413–6.

    Article  CAS  PubMed  Google Scholar 

  41. Gough DB, Donohue JH, Evans MM, et al. A 50 year experience of male breast cancer: is outcome changing? Surg Oncol. 1993;2:325–33.

    Article  CAS  PubMed  Google Scholar 

  42. DeCicco C, Baio SM, Veronesi P, et al. Sentinel node biopsy in male breast cancer. Nucl Med Commun. 2004;25:139–43.

    Article  Google Scholar 

  43. Port ER, Fey JV, Cody HS3rd et al. Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer. 2001;91:319–323.

    Google Scholar 

  44. Donegan WL, Redlich PN, Lang PJ, et al. Carcinoma of the breast in males: a multiinstitutional survey. Cancer. 1998;83:498–509.

    Article  CAS  PubMed  Google Scholar 

  45. Perkins GH, Middleton LP, Garcia SM, et al. Male breast carcinoma: outcomes and predictors of local-regional failure in patients treated without radiation therapy. Breast Cancer Res Treat. 2002;76:121.

    Google Scholar 

  46. Bagley CS, Wesley MN, Young RC, et al. Adjuvant chemotherapy in males with cancer of the breast. An J Clin Oncol. 1987;10:55–60.

    Article  CAS  Google Scholar 

  47. Giordano SH, Perkins GH, Broglio K, et al. Adjuvant systemic therapy for male breast carcinoma. Cancer. 2005;104:2359–64.

    Article  PubMed  Google Scholar 

  48. Jaiyesimi IA, Buzdar AU, Sahin AA, et al. Carcinoma of the male breast. Ann Intern Med. 1992;117(9):771–7.

    Article  CAS  PubMed  Google Scholar 

  49. Kantarjian H, Yap HY, Hortobagyi G, et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983;143(2):237–40.

    Article  CAS  PubMed  Google Scholar 

  50. Riberio G. Tamoxifen in the treatment of male breast carcinoma. Clin Radiol. 1983;34:625–8.

    Article  Google Scholar 

  51. Riberio G, Swindell R. Adjuvant tamoxifen for male breast cancer. Br J Cancer. 1992;65:252–4.

    Article  Google Scholar 

  52. Anelli TF, Anelli A, Tran KN, et al. Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer. 1994;74(1):74–7.

    Article  CAS  PubMed  Google Scholar 

  53. Kantarjian H, Yap HY, Hortobagyi G, et al. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983;143(2):237–40.

    Article  CAS  PubMed  Google Scholar 

  54. Pemmaraju N, Munsell MF, Hortobagyi GN, et al. Retrospective review of male breast cancer patients: analysis of tamoxifen-related side effects. Ann Oncol. 2012;23(6):1471–4.

    Article  CAS  PubMed  Google Scholar 

  55. Ferzoco RM, Ruddy KJ. Optimal delivery of male breast cancer follow-up care: improving outcomes. Breast Cancer Targets Ther. 2015;7:371–9.

    Google Scholar 

  56. Nahleh Z, Girnius S. Male breast cancer: a gender issue. Nat Clin Pract Oncol. 2015;3:428–37.

    Article  Google Scholar 

  57. Czene K, Bergqvist J, Hall P, Bergh J. How to treat male breast cancer. Breast. 2007;16:S147–54.

    Article  PubMed  Google Scholar 

  58. Giordano SH. A review of the diagnosis and management of male breast cancer. Oncologist. 2005;10:471–9.

    Article  PubMed  Google Scholar 

  59. Shak S, Palmer G, Baehner FL, et al. Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: first large genomic study of 347 male breast cancers compared to 82,434 female breast cancers. J Clin Oncol (Meet Abstr). 2009;27:549.

    Google Scholar 

  60. Hung MH, Liu CJ, Teng CJ, et al. Risk of second non-breast primary cancer in male and female breast cancer patients: a population-based cohort study. PLoS ONE. 2016;11(2):e01485972016.

    Google Scholar 

  61. Shi R, Taylor H, Liu L, et al. Private Payer’s status improves male breast cancer survival. Breast J. 2016;22(1):101–4.

    Article  PubMed  Google Scholar 

  62. National Comprehensive Cancer Network. (2016). NCCN Guidelines: Genetic/Familial High Risk Assessment: Breast and Ovarian. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf.

  63. National Comprehensive Cancer Network. (2016). NCCN Guidelines: Breast Cancer. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.

  64. Kirchhoff T, Kauff N, Kolachana P, et al. BRCA mutations and the risk of prostate and colorectal cancer in Ashkenazi Jews. Am J Human Genet. 2003;73(5):246.

    Google Scholar 

  65. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56(23):5360–4.

    CAS  PubMed  Google Scholar 

  66. Risch HA, McLaughlin JR, Cole DEC, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Human Genet. 2001;68(3):700–10.

    Article  CAS  Google Scholar 

  67. Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22(4):735–42.

    Article  CAS  PubMed  Google Scholar 

  68. Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers: a review. Breast. 2008;17:441–50.

    Article  PubMed  Google Scholar 

  69. Fentiman IS. Male breast cancer is not congruent with the female disease. Crit Rev Oncol Hematol. 2016;101:119–24.

    Article  PubMed  Google Scholar 

  70. Chun DS, Berse B, Venne VL, et al. BRCA testing within the department of veterans affairs: concordance with clinical practice guidelines. Fam Cancer 2016 Epub ahead of print. (PMID: 27589855 Doi:10.1007/s10689-016-9921-5).

  71. Hesse-Bilber S, An C. Within-gender differences in medical decision making among male carriers of the BRCA genetic mutation for hereditary breast cancer. Am J Mens Health. 2015 Oct 14. pii: 1557988315610806. [Epub ahead of print].

    Google Scholar 

  72. Kwiatkowski F, Arbre M, Bidet Y, et al. BRCA Mutation increase fertility in families at heterditary breast/ovarian cancer risk. PLos One 2015 June 5:10(6) doi:10.1371.

    Google Scholar 

  73. Alanee S, Glogowski E, Kasminta A, et al. Clinical features and management of BRCA1 and BRCA2 associated prostate cancer. Front Biosci. 2014;6:15–30.

    Article  Google Scholar 

  74. Borgen PI, Senie RT, McKinnon WM, et al. Carcinoma of the male breast: analysis of prognosis compared with matched female patients. Ann Surg Oncol. 1997 Jul-Aug;4(5):385–388.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery, Maimonides Medical Center, 4802 10th Avenue, Brooklyn, NY, 11219, USA

    Donna-Marie Manasseh, Ryland J. Gore & Patrick I. Borgen

Authors
  1. Donna-Marie Manasseh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryland J. Gore
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick I. Borgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick I. Borgen .

Editor information

Editors and Affiliations

  1. Yale Comprehensive Cancer Center, Yale University School of Medicine Yale Comprehensive Cancer Center, New Haven, Connecticut, USA

    Anees B. Chagpar

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

Manasseh, DM., Gore, R.J., Borgen, P.I. (2017). Management of Male BRCA Mutation Carriers. In: B. Chagpar, A. (eds) Managing BRCA Mutation Carriers . Springer, Cham. https://doi.org/10.1007/978-3-319-59198-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59198-8_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59197-1

  • Online ISBN: 978-3-319-59198-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation